Skip to main content
Loading
  • Catalyst: Our Highlights from hubXchange Immunotherapies Maryland 2024

    Meredith Manuel, Executive Director - Consulting, Catalyst
    Optimizing Dose and Leveraging Biomarkers for Enhanced Patient Safety in Immunotherapy Trials HubXchange Immunotherapies brought together almost 40 senior-level scientists and executives from the phar ...
  • Tumor cells have developed sophisticated mechanisms to evade the immune system, posing significant challenges to effective cancer treatment. Recent research has elucidated several key strategies emplo ...
  • The University of Birmingham has launched Europe's first clinical trial investigating the use of an mRNA-based vaccine to combat pancreatic cancer, a significant advance in personalized cancer immunot ...
  • In the rapidly evolving landscape of precision medicine, one of the greatest challenges lies in predicting individual patient responses to therapeutic agents. Drug efficacy and toxicity can vary widel ...
  • The use of machine learning (ML) in the analysis of vast biological datasets is revolutionizing our approach to drug discovery, personalized medicine, and therapeutic outcome prediction. As senior sci ...
  • Farcast Biosciences, a research solutions company and developer of the TruTumor platform—a large fragment, near-native tumor preservation and histo-culture platform enabling precision tumor microenvir ...
  • Nanotechnology, once confined to the realm of theoretical research, is now revolutionizing biomedical science, particularly in cancer diagnostics and therapy. Nanorobots, designed with the capacity to ...
  • BNT116, developed by BioNTech, is an advanced mRNA-based therapeutic vaccine designed specifically to target non-small cell lung cancer (NSCLC). This vaccine falls within the broader scope of BioNTech ...
  • In the dynamic and rapidly evolving field of antibody therapeutics, the ability to identify targets with optimal therapeutic windows is a critical determinant of clinical success. The therapeutic wind ...